What happened with the FDA and compounded GLP-1s, and who is still operating legally?

Short answer

• The FDA has taken a hard line: compounding copies of FDA‑approved GLP‑1 biologics (semaglutide, tirzepatide, etc.) is legally and medically risky. The agency has warned/targeted some compounding operations and made it clear that making and distributing unapproved “copies” of approved biologic GLP‑1 drugs can violate federal law.
• That doesn’t mean every compounding pharmacy shut down — but only pharmacies that follow the specific federal and state compounding rules may legally continue, and many prescribers/pharmacies have stopped offering compounded GLP‑1s because of safety, legal and enforcement risk.

What led to this

• GLP‑1 peptides (semaglutide, tirzepatide and similar molecules) are biologics/complex peptides that the FDA approves as prescription products (examples below). The FDA’s position: wholesale copying/production of approved biologics through compounding can create safety risks (sterility, dose variability, contaminated APIs) and may be inconsistent with federal law (sections of the FD&C Act that limit compounding of approved drugs/biologics).
• In response, the FDA issued guidance and enforcement (warning letters, public statements and some seizures/inspections) aimed at pharmacies and clinics compounding and marketing unapproved GLP‑1 products. As a result many operators stopped or curtailed compounding GLP‑1s rather than risk enforcement.

Who can still operate legally

• 503A compounding pharmacies: They may compound drug products for an individual patient pursuant to a valid prescription under state board rules and federal law — but compounding a product that is essentially a copy of an FDA‑approved biologic is generally disfavored or restricted. Whether a particular pharmacy can legally compound a GLP‑1 depends on state law, the clinical justification, and whether the product truly differs from an approved product.
• 503B outsourcing facilities: These are FDA‑regulated facilities that can compound drugs in bulk, must follow current good manufacturing practices (cGMP), and must register with the FDA. Even so, the FDA has signaled limits on compounding copies of approved biologics; 503B status doesn’t automatically make compounding of an approved biologic legal.
• Retail and specialty pharmacies dispensing FDA‑approved GLP‑1 products (prescribed by a licensed clinician) are fully legal and are the safest route.

How to tell if a provider is operating legally and safely

• Ask whether the product is an FDA‑approved drug (brand/generic name) or a compounded product.
• If compounded: ask whether the pharmacy is a state‑licensed 503A pharmacy or an FDA‑registered 503B outsourcing facility; ask for evidence of sterility testing, certificate of analysis for the API (source/manufacturer), and adherence to USP standards (e.g., USP <797>).
• Check the state board of pharmacy and FDA (503B facility list) for registration and disciplinary history.
• If a clinic or company markets “cheap” injectable semaglutide/tirzepatide without an individualized prescription or wide distribution, be very cautious — that’s the kind of practice the FDA has targeted.

Safer, recommended alternatives (brands/services)

• Use FDA‑approved GLP‑1s through your prescriber and a reputable pharmacy:
  • Ozempic (semaglutide — Novo Nordisk): approved for type 2 diabetes; widely prescribed and supported by manufacturer patient support programs.
  • Wegovy (semaglutide — Novo Nordisk): approved for chronic weight management (higher dose than Ozempic).
  • Mounjaro (tirzepatide — Eli Lilly): approved for type 2 diabetes; has strong clinical data.
  • Zepbound (tirzepatide — Eli Lilly): approved for weight management (if available in your region).
• Go through mainstream channels: your PCP/endocrinologist/weight‑management specialist, retail pharmacies (CVS, Walgreens, Rite Aid) or accredited specialty pharmacies. These routes ensure real product, cold‑chain handling, and proper monitoring.

Practical next steps

• Talk with your prescriber about whether an FDA‑approved GLP‑1 is right for you.
• If you encounter a compounded GLP‑1 offer and are tempted by price/availability, ask the pharmacy for documentation (503B registration or state license, COA, sterility/assay testing). If they can’t supply these, don’t use it.
• Contact your state board of pharmacy or the FDA if you suspect illegal/unapproved distribution.

If you want, I can:

• Help you find nearby clinics or telehealth services that prescribe FDA‑approved GLP‑1s.
• Walk you through specific questions to ask a compounding pharmacy to assess safety/legal compliance.